Lowe’s Q2 Highlights: Flat Sales, Bottom-Line Beat, Sluggish DIY Trends & More

Lowe’s Companies Inc (NYSE:LOW) reported a second-quarter FY22 sales decline of 0.34% year-on-year to $27.48 billion, missing the consensus of $28.14…
  • Lowe’s Companies Inc (NYSE:LOW) reported a second-quarter FY22 sales decline of 0.34% year-on-year to $27.48 billion, missing the consensus of $28.14 billion.
  • Comparable sales decreased 0.3%, while comparable sales for the U.S. home improvement business rose 0.2%.
  • DIY sales were impacted by the shortened spring and lower demand in certain discretionary categories.
  • EPS of $4.67 beat the analyst consensus of $4.62.
  • Gross profit fell 1.9% Y/Y to $9.1 billion, with a profit margin contracting 54 basis points to 33.24%.
  • The operating margin expanded 12 basis points to 15.39%, and operating income for the quarter rose 0.5% to $4.2 billion.
  • The company held $1.9 billion in cash and equivalents as of July 29, 2022. Net cash provided by operating activities for the six months totaled $6 billion.
  • Outlook: Lowe’s now expects FY22 total and comparable sales toward the bottom end of its outlook range and expects operating income and EPS toward the top end of its outlook range.
  • LOW’s FY22 sales outlook ranges at $97 billion – $99 billion versus the consensus of $97.54 billion.
  • FY22 EPS forecast ranges at $13.10 – $13.60, against the consensus of $13.39.
  • Price Action: LOW shares are trading higher by 3.21% at $221.00 in premarket on the last check Wednesday.
  • Photo Via Wikimedia Commons
Total
0
Shares
Related Posts
Read More

Immuron Announced US DoD Naval Medical Research Center Received feedback on IND Application for New Campylobacter ETEC Therapeutic; Said IND Does Not Contain Sufficient Information

:Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic products for the prevention and treatment of gut pathogens, today announced that the US Naval Medical Research Center (NMRC) has received feedback from the US Food and Drug Administration following a review of the Investigational New Drug (IND) applica

IMRN